#Japan #Nagoya #ADC technology #K-679 #Kowa Company

K-679: A Novel Antibody-Drug Conjugate for Targeted Cancer Therapy

In recent developments, Kowa Company, Ltd., headquartered in Nagoya, Aichi, Japan, has unveiled promising data on a novel unimicelle-based antibody-drug conjugate (ADC) named K-679. This innovative therapeutic compound is poised to revolutionize cancer treatment by displaying selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in non-clinical animal models. Kowa is set to present its findings at the American Association for Cancer Research (AACR) Annual Meeting in 2026, scheduled in San Diego, California, from April 17 to 22.

Overview of K-679

The K-679 compound is designed to combat solid tumors expressing the epidermal growth factor receptor (EGFR). Developed using Kowa's proprietary micellar technology, K-679 significantly enhances drug delivery to targeted tumor sites. This ADC combines EGFR-targeting antibodies with unimicelles and incorporates a substantial drug payload (DM1), achieving an unprecedented drug-to-antibody ratio (DAR) of approximately 45 molecules of DM1 per antibody. This ratio is markedly higher than that of conventional ADCs, allowing for more effective tumor targeting and reduction of side effects.

Key Findings from Preclinical Studies

Recent preclinical evaluations highlight the distinct advantage of K-679 compared to traditional ADCs. The compound demonstrates:

• - Selective Pharmacokinetics: K-679 exhibits a unique distribution profile that favors tumor localization while minimizing systemic exposure, which is crucial for enhancing therapeutic efficacy and reducing potential toxicity.
• - Intratumoral Distribution: The micellar nature of K-679 allows for an extensive distribution within the tumor, ensuring that the therapeutic agent reaches various tumor cells effectively.
• - Efficacy Against EGFR-expressing Tumors: In xenograft models, including patient-derived xenografts (PDX), K-679 shows notable anti-tumor activity against colorectal cancer with low and heterogeneous EGFR expression, validating its potential as a versatile treatment option.

Presentation at AACR 2026

Kowa Company plans to present the data in a session titled “Technologies and Platforms of Antibodies 2” on April 21, 2026, from 9:00 AM to 12:00 PM CST (10:00 AM to 1:00 PM ET). The abstract, numbered 4396, will delve into the selective intratumoral distribution and activity of K-679 following treatment with T-DXd, further elucidating the potential applications of this advanced ADC technology.

Media Contact

For more information regarding the research and upcoming presentation, reporters can reach out to Ian Mehr at Kowa Research Institute, Inc., via phone at 919-433-1600 or by email at [email protected].

Conclusion

K-679 represents a significant advancement in antibody-drug conjugate technology, offering hope for improved cancer treatment options. With ongoing research and development, Kowa Company is poised to contribute substantially to oncology therapeutics, and the upcoming AACR 2026 presentation is highly anticipated within the medical community.

By leveraging its innovative technology, Kowa aims to enhance the precision and efficacy of cancer therapies, ultimately improving patient outcomes in the fight against cancer.